BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 19942948)

  • 21. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer.
    Tugues S; Koch S; Gualandi L; Li X; Claesson-Welsh L
    Mol Aspects Med; 2011 Apr; 32(2):88-111. PubMed ID: 21565214
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of vascular endothelial growth factor (VEGF) and its receptors (Flt-1 and Flk-1) in esophageal squamous cell carcinoma.
    Kato H; Yoshikawa M; Miyazaki T; Nakajima M; Fukai Y; Masuda N; Fukuchi M; Manda R; Tsukada K; Kuwano H
    Anticancer Res; 2002; 22(6C):3977-84. PubMed ID: 12553021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms.
    Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K
    Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
    Wood JM; Bold G; Buchdunger E; Cozens R; Ferrari S; Frei J; Hofmann F; Mestan J; Mett H; O'Reilly T; Persohn E; Rösel J; Schnell C; Stover D; Theuer A; Towbin H; Wenger F; Woods-Cook K; Menrad A; Siemeister G; Schirner M; Thierauch KH; Schneider MR; Drevs J; Martiny-Baron G; Totzke F
    Cancer Res; 2000 Apr; 60(8):2178-89. PubMed ID: 10786682
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression.
    Hanrahan V; Currie MJ; Gunningham SP; Morrin HR; Scott PA; Robinson BA; Fox SB
    J Pathol; 2003 Jun; 200(2):183-94. PubMed ID: 12754739
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.
    Ljungberg BJ; Jacobsen J; Rudolfsson SH; Lindh G; Grankvist K; Rasmuson T
    BJU Int; 2006 Sep; 98(3):661-7. PubMed ID: 16925769
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Upregulation of serum and tissue vascular endothelial growth factor correlates with angiogenesis and prognosis of oral squamous cell carcinoma.
    Shang ZJ; Li JR; Li ZB
    J Oral Maxillofac Surg; 2007 Jan; 65(1):17-21. PubMed ID: 17174758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumor cell and endothelial cell therapy of oral cancer by dual tyrosine kinase receptor blockade.
    Yigitbasi OG; Younes MN; Doan D; Jasser SA; Schiff BA; Bucana CD; Bekele BN; Fidler IJ; Myers JN
    Cancer Res; 2004 Nov; 64(21):7977-84. PubMed ID: 15520205
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of vascular endothelial growth factor and microvessel density in head and neck tumorigenesis.
    Tae K; El-Naggar AK; Yoo E; Feng L; Lee JJ; Hong WK; Hittelman WN; Shin DM
    Clin Cancer Res; 2000 Jul; 6(7):2821-8. PubMed ID: 10914730
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of vascular endothelial growth factor (VEGF) in oral dysplasia and oral squamous cell carcinoma.
    Johnstone S; Logan RM
    Oral Oncol; 2006 Apr; 42(4):337-42. PubMed ID: 16144770
    [TBL] [Abstract][Full Text] [Related]  

  • 31. S-1 inhibits tumorigenicity and angiogenesis of human oral squamous cell carcinoma cells by suppressing expression of phosphorylated Akt, vascular endothelial growth factor and fibroblast growth factor-2.
    Harada K; Supriatno ; Kawashima Y; Yoshida H; Sato M
    Int J Oncol; 2007 Feb; 30(2):365-74. PubMed ID: 17203218
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of vascular endothelial growth factors and their receptors in malignant melanomas.
    Brychtova S; Bezdekova M; Brychta T; Tichy M
    Neoplasma; 2008; 55(4):273-9. PubMed ID: 18505336
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene.
    Belletti B; Ferraro P; Arra C; Baldassarre G; Bruni P; Staibano S; De Rosa G; Salvatore G; Fusco A; Persico MG; Viglietto G
    Oncogene; 1999 Aug; 18(34):4860-9. PubMed ID: 10490819
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Regional difference in intratumoral lymphangiogenesis of oral squamous cell carcinomas evaluated by immunohistochemistry using D2-40 and podoplanin antibody: an analysis in comparison with angiogenesis.
    Ohno F; Nakanishi H; Abe A; Seki Y; Kinoshita A; Hasegawa Y; Tatematsu M; Kurita K
    J Oral Pathol Med; 2007 May; 36(5):281-9. PubMed ID: 17448138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma.
    Vacca A; Ria R; Ribatti D; Semeraro F; Djonov V; Di Raimondo F; Dammacco F
    Haematologica; 2003 Feb; 88(2):176-85. PubMed ID: 12604407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vascular endothelial growth factor--a positive and negative regulator of tumor growth.
    Vecchiarelli-Federico LM; Cervi D; Haeri M; Li Y; Nagy A; Ben-David Y
    Cancer Res; 2010 Feb; 70(3):863-7. PubMed ID: 20103650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The direct effects of anti-vascular endothelial growth factor therapy on tumor cells.
    Moser C; Lang SA; Stoeltzing O
    Clin Colorectal Cancer; 2007 Jul; 6(8):564-71. PubMed ID: 17681102
    [TBL] [Abstract][Full Text] [Related]  

  • 38. KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells.
    Yoshiji H; Kuriyama S; Hicklin DJ; Huber J; Yoshii J; Miyamoto Y; Kawata M; Ikenaka Y; Nakatani T; Tsujinoue H; Fukui H
    Hepatology; 1999 Nov; 30(5):1179-86. PubMed ID: 10534339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular permeability factor/vascular endothelial growth factor and its receptors in oral and laryngeal squamous cell carcinoma and dysplasia.
    Denhart BC; Guidi AJ; Tognazzi K; Dvorak HF; Brown LF
    Lab Invest; 1997 Dec; 77(6):659-64. PubMed ID: 9426404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mutual paracrine effects of oral squamous cell carcinoma cells and normal oral fibroblasts: induction of fibroblast to myofibroblast transdifferentiation and modulation of tumor cell proliferation.
    Kellermann MG; Sobral LM; da Silva SD; Zecchin KG; Graner E; Lopes MA; Kowalski LP; Coletta RD
    Oral Oncol; 2008 May; 44(5):509-17. PubMed ID: 17826300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.